Fortress Biotech Inc Stock Price, News & Analysis

Journey Medical (NASDAQ: DERM) reported net revenues of $19.6 million for Q3 2021, a 108% increase from $9.4 million in Q3 2020. The company completed its initial public offering, raising $31.2 million in net proceeds. Although the net loss for Q3 2021 was $10.6 million ($1.16 per share), this was an improvement compared to a net loss of $22.2 million ($2.43 per share) in Q3 2020. Journey Medical anticipates dosing the first patient in its Phase 3 clinical program for DFD-29 in Q1 2022 while expanding its leadership team.

Journey Medical Corporation (NASDAQ: DERM) announced its participation at the Benzinga Global Small Cap Conference, taking place virtually from December 8-9, 2021. CEO Claude Maraoui and CFO Ernie De Paolantonio will present a corporate overview on December 9 at 11:10 AM EST. They will also be available for one-on-one meetings during the conference. Journey Medical specializes in developing and commercializing products for dermatological conditions and was founded by Fortress Biotech (NASDAQ: FBIO).

Cyprium Therapeutics, a partner of Fortress Biotech (FBIO), has initiated a rolling submission of a New Drug Application (NDA) for CUTX-101 to the FDA for treating Menkes disease. The submission is expected to complete in mid-2022. Positive results from pivotal studies demonstrate CUTX-101's safety and efficacy, and the drug has received several FDA designations. If approved, CUTX-101 could be the first treatment for this rare disease, addressing a significant unmet need. Fortress stands to receive up to $20 million in milestones and continues to oversee CUTX-101's development.

Journey Medical Corporation (NASDAQ: DERM) has expanded its board of directors, admitting four new independent members: Jeffrey Paley, M.D., Justin Smith, Miranda Toledano, and Neil Herskowitz. This strategic move supports the company following its recent IPO. Executive Chairman Lindsay Rosenwald emphasized the new board members' extensive expertise in finance and dermatology, aiming to drive growth and commercialization of dermatological products. Journey Medical currently has seven marketed products and one in clinical development, indicating potential for future expansion.

Journey Medical Corporation (NASDAQ: DERM) has closed its initial public offering, successfully selling 3,520,000 shares at $10.00 each, raising gross proceeds of $35.2 million. The proceeds will be allocated towards general corporate purposes, including research and development, marketing, and potential acquisitions. The offering was managed by B. Riley Securities, with Roth Capital Partners as a co-manager. Journey Medical specializes in dermatological products and aims to leverage its capital for growth in the competitive pharmaceutical market.

Fortress Biotech (NASDAQ: FBIO) reported a remarkable 123% year-over-year increase in net revenue, reaching a record $21.1 million for Q3 2021. The company’s partner, Journey Medical Corporation, successfully launched its $35.2 million IPO. Fortress also received $56.9 million from AstraZeneca following its acquisition of Caelum Biosciences. Upcoming initiatives include a rolling NDA submission for CUTX-101 and top-line results for cosibelimab expected by year-end 2021. Operating expenses rose significantly, with R&D expenses totaling $28.1 million for the quarter.

Aegis Capital Corp. has successfully completed a $2.6 million public offering of common stock for Avenue Therapeutics (NASDAQ: ATXI). The funds raised through this offering are aimed at advancing Avenue's mission to develop IV tramadol, a potential alternative to conventional opioids for acute pain management in the U.S. Avenue Therapeutics was founded by Fortress Biotech (NASDAQ: FBIO) and is positioned to address the growing need for effective pain relief solutions.

Journey Medical Corporation (NASDAQ: DERM) has priced its initial public offering (IPO) at $10 per share, raising gross proceeds of $35.2 million. The company, a subsidiary of Fortress Biotech (NASDAQ: FBIO), will receive approximately $31.4 million in net proceeds after expenses. The IPO is set to close on November 16, 2021, with common stock starting to trade on November 12, 2021. Proceeds will support working capital, R&D, marketing, and potential acquisitions.

Journey Medical Corporation has launched an initial public offering (IPO) of 3,200,000 shares of common stock, expected to price between $10 and $12 per share. The company, a subsidiary of Fortress Biotech (FBIO), may also allow underwriters to purchase an additional 480,000 shares. Journey Medical aims to list its shares on The Nasdaq Capital Market under the symbol ‘DERM.’ B. Riley Securities is the sole book-running manager, with Roth Capital Partners as a co-manager. The offering is subject to market conditions and regulatory approval.